According to IMS data Xeloda made by Genentech, had $754 million in US sales in 2013.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces the launch of the generic equivalent to Xeloda (Capecitabine) Tablets, 150 MG and 500 MG, in the United States.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Xeloda is marketed by Genentech in the United States. Teva was the first to receive approval on its ANDA from the U.S. Food and Drug Administration on September 16, 2013 and is launching today per a settlement agreement.
Xeloda (Capecitabine) Tablets, 150 MG and 500 MG had annual sales of approximately $754 million in the United States, according to IMS data as of December, 2013.